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Abstract
Background: Although the beneficial effects of vaccines on equity by socioeconomic status and geography are
increasingly well-documented, little has been done to extend these analyses to examine the linkage between
vaccination and gender equity. In this paper, evidence from the published literature is used to develop a
conceptual framework demonstrating the potential impact of vaccination on measures of gender equity. This
framework is then applied to human papillomavirus (HPV) vaccination in three countries with different economic
and disease burden profiles to establish a proof of concept in a variety of contexts.
Methods: We conducted a literature review examining evidence on the linkage between health outcomes and
dimensions of gender equity. We utilized the Papillomavirus Rapid Interface for Modelling and Economics (PRIME)
model to estimate cervical cancer incidence and deaths due to HPV types 16/18 by age in each country. We
estimated labor force participation and fertility effects from improvements in health, and converted these into
inputs consistent with those used to calculate the United Nations Gender Inequality Index to assess gender equity.
Results: In our case study, we found that HPV vaccination among girls could help narrow socioeconomic gender
disparities by quantifying the main pathways by which HPV vaccination improves health, which enables
improvement in gender equity indicators such as labor force participation and maternal mortality ratios. While
these improvements are small when averaged over the entire population, the components measured – labor force
participation and maternal mortality ratio – account for 50% of the index scores.
Conclusions: This proof of concept model is a starting point to inform future health and economic analyses that
might incorporate the impact of gender equity as an additional impact of vaccination in improving the health and
well-being of the population.
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Background
Vaccines are one of the most effective public health innova-
tions in the past century. Every year immunizations save be-
tween two and three million lives and avert billions of
dollars in costs of illness [1]. Not only are most vaccines
cost-effective [2], but childhood immunizations are esti-
mated to have a return on investment of 16 to 44 times the
costs in the current decade [3]. Beyond saving lives, improv-
ing health and enhancing economic growth, vaccines also
deliver wider societal benefits [4]. For example, vaccination
can impact children’s cognitive development [5–7] and edu-
cational attainment [8–10]. Moreover, vaccination has been
found to improve equity by reducing income-related dispar-
ities and reducing poverty [11–13]. Although the beneficial
effects of vaccines on equity by socioeconomic status and
geography are increasingly well-documented, little has been
done to extend these analyses to examine the linkage be-
tween vaccination and gender equity.
Achieving gender equity and empowering all women
and girls is one of the United Nations’ Sustainable
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Development Goals and a key foundation for a peaceful,
prosperous, and sustainable world [14]. Gender inequity
relates to health as gender-related power imbalances con-
tribute to excess female mortality, gender-based violence,
and limited health-seeking behaviors including lower ac-
cess to reproductive healthcare [15, 16]. When women and
girls receive healthcare, are educated, are not married as a
child, and can earn and control income, economies expand
and cycles of poverty are broken [17]. While one suggested
approach has been to target these conditions directly with
policy [17], we sought to examine the link in the other dir-
ection from health to development, i.e., whether vaccin-
ation in turn can contribute to gender equity.
The linkage between vaccines and gender equity is
particularly relevant in the case of the human papilloma-
virus (HPV) vaccine. HPV vaccine studies demonstrate
an almost 100% protection against the previously high-
risk HPV strains that cause cervical cancer (types 16 and
18), and HPV vaccines have been shown to be cost-
effective in most settings [18–20]. While HPV causes
disease in both females and males, globally almost 90%
of the HPV vaccine-preventable disease burden falls on
females [21]. In women, cervical cancer is the second
leading cause of new cases of cancer and cancer death
worldwide [22]. Hence we hypothesize that HPV vaccin-
ation among girls could help narrow socioeconomic gen-
der disparities by reducing the cervical cancer burden
that women experience and increasing the opportunities
afforded by improved health.
In this paper, evidence from the published literature is
used to develop a conceptual framework demonstrating
the potential impact of vaccination on measures of gen-
der equity. This framework is then applied to the HPV
vaccine example in three countries with different eco-
nomic and disease burden profiles to establish the im-
pact of improved health on gender equity in a variety of
development contexts. Our objective is to provide a
proof of concept model as a starting point to inform fu-
ture analyses that seek to estimate the health and eco-
nomic impact of gender equity.
Methods
Literature review on the linkage between health
outcomes and gender equity dimensions
We first conducted a literature review using two data-
bases (PubMed and Web of Science) examining studies
on gender equity and health impact published between
January 1, 1980 and December 31, 2018. The search
strategy used a combination of free text terms across all
search fields. Key search terms included those related to
gender equity and health impact (“gender equity” OR
“gender inequality” OR “gender gap”) AND “impact”
AND “health). Record titles and abstracts were screened
by a single reviewer to identify studies that met the
inclusion criteria. Articles that did not discuss gender
equity, did not look at health impact, were not human
studies, contained outcomes from a study already re-
ported in another article, or contained a non-English ab-
stract were excluded. Key working papers regarding the
topic of gender equity were also included. From each of
the included studies, we extracted information on the di-
mension(s) of gender equity included and the linkage(s)
between health outcomes and gender equity.
Modeling the impact of HPV vaccination on gender equity
We modeled the impact that HPV vaccination among
girls could have on gender equity in a low-, middle-, and
high-income country (Tanzania, India, and the United
Kingdom), where each country represents a different
level of disease burden. Compared to the worldwide an-
nual cervical cancer incidence of 14.0 per 100,000 popu-
lation [23], Tanzania has a high burden with an
incidence of 30.6 [24], India has a medium burden with
an incidence of 20.2 [25], and the United Kingdom has a
low burden with an incidence of 9.5 per 100,000 popula-
tion [26]. We utilized the Papillomavirus Rapid Interface
for Modelling and Economics (PRIME) model to esti-
mate cervical cancer incidence and deaths due to HPV
types 16/18 by age in each country. PRIME is a static,
proportional outcomes model that can project the epi-
demiological and economic outcomes of HPV vaccin-
ation of young adolescent women. Specifically, PRIME
estimates reductions in age-specific cervical cancer in
direct proportion to vaccine efficacy against HPV 16/18,
vaccine coverage, and HPV type distribution. It has been
used to inform investment decisions by Gavi, the Vac-
cine Alliance, and the Bill & Melinda Gates Foundation.
It has been extensively documented and validated [18];
an Excel-based version of PRIME is freely available at
primetool.org. Relevant country- and age-specific inputs
for PRIME are provided in the Additional file 1.
In this analysis, we assumed a scenario of 80% cover-
age of HPV vaccination with a two-dose regimen. The
impact of this HPV vaccination scenario on cervical can-
cer incidence and death projected by PRIME is aug-
mented with the extracted literature review data on the
linkages between health outcomes and dimensions of
gender equity. Based on evidence from the literature, we
developed a conceptual pathway by which HPV vaccin-
ation can improve healthy life expectancy in women,
which can in turn improve their labor force participation
and decrease fertility, and hence narrow a key source of
gender disparities in many countries [27]. Labor force
participation and maternal mortality were selected as
criteria for reducing gender disparities given their inclu-
sion in multiple gender equity measures and linkage to
improved female health [15, 27–35]. We were unable to
quantify the effect of improved healthy life expectancy
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on maternal mortality directly, but instead assumed that
decreased fertility led to an associated decrease in mater-
nal mortality.
To quantify the magnitude of these relationships, we
first converted years of life expectancy to years of
healthy life expectancy utilizing life tables and healthy
life expectancy at birth and at age 60 from the World
Health Organization (WHO) for Tanzania, India, and
the United Kingdom [36]. Given currently published
WHO estimates of healthy life expectancy at birth and
at age 60, we created multipliers from the level of life ex-
pectancy to healthy life expectancy at these two ages.
We used these multipliers to adjust the life expectancy
curves from birth to age 60 to approximate years of
healthy life expectancy for each age. Between age 60 and
100, we used the same approach given the points of
healthy life expectancy at age 60 from the WHO and an
assumption of 0.5 for remaining healthy life expectancy
at age 100 to create new multipliers to adjust the life ex-
pectancy curves.
Using these estimates of healthy life expectancy, we as-
sumed that the decreased cervical cancer incidence and
deaths from HPV vaccination yielded decreased years
lived with disability (YLDs) and decreased years of life
lost (YLLs). The ratio of the decreased YLDs and YLLs
to healthy life years gained compared to total YLDs and
YLLs to total healthy life expectancy was interpreted as
the percentage improvement in health due to HPV vac-
cination. This percentage improvement in health trans-
lated to percentage increases in labor force participation
and percentage reductions in fertility rate, utilizing per-
centages calculated from evidence identified through the
literature review. According to a working paper by
Bloom, et al., we assumed that a 5% improvement in
health from HPV vaccination translated to a 5.9% in-
crease in female labor force participation and a 2.4% re-
duction in fertility [27]. These percentages reflect years
of healthy life lost due to disability for the age groups
15–29 and 30–49, which are assumed to span the poten-
tial period of fertility (ages 15–35) and child-rearing
(ages 35–50) for women. We also examined what the
improvements would be if the magnitude of the associa-
tions were half or twice these values through sensitivity
analyses.
The impact of HPV vaccination on overall gender dis-
parities was assessed by converting previously estimated
labor force participation and fertility effects into inputs
consistent with those used to calculate the United Na-
tions (UN) Gender Inequality Index (GII) [37, 38]. The
GII is based on the UN Human Development Index and
provides a quantitative measure of the human develop-
ment costs of gender inequality along three dimensions:
(1) reproductive health (e.g., maternal mortality ratio
and adolescent birth rates); (2) empowerment (e.g.,
proportion of parliamentary seats held and secondary
education attainment); and (3) economic status (e.g.,
labor force participation). While labor force participation
could be directly incorporated into the GII calculation,
fertility changes had to be converted to a corresponding
GII input (in this case, maternal mortality ratios) using
estimates of the relationship between fertility and mater-
nal mortality from the published literature [39]. We
therefore estimated the years of employment gained ac-
cording to the percentage improvements in labor force
participation and associated improvements in healthy life
expectancy when applied across the total population by
five-year age groups. We multiplied the years of employ-
ment gained by country gross domestic product (GDP)
per capita in order to estimate improvements in eco-
nomic productivity. We assumed that all additional years
of healthy life expectancy during productive working age
(i.e., ages 15 to 49) translated to years of employment
gained. Similarly, we estimated the maternal deaths
averted according to the percentage improvements in
maternal mortality ratios from associated reductions in
fertility rates.
Once the relevant inputs were derived, the impact of
HPV vaccination on GII scores were calculated by sub-
tracting the current index value from the counterfactual
index value under a hypothetical 0% HPV vaccine cover-
age scenario. Since higher GII scores are associated with
greater inequality, the difference between these two
values can be interpreted as the reduction in inequality
associated with HPV vaccination.
Results
Findings from the literature review on the linkage
between health outcomes and gender equity
Our review of dimensions of gender equity identified five
relevant articles [15, 33, 34, 37, 38] on gender equity in-
dices. The gender development index (GDI) of the
United Nations Development Program (UNDP) includes:
life expectancy, literacy rate, school enrollment, and eco-
nomic activity [15, 37]. The gender empowerment mea-
sures (GEM) of UNDP includes: female representation
in the government and the labor force [15]. The Gender
Equity Index (GEI) includes: education, economic activ-
ity, and empowerment (i.e., political participation, repre-
sentation in government positions, law-making) [37].
The Gender Gap Index (GGI) includes: economic devel-
opment, education, health, survival, and political partici-
pation [37]. The Gender Parity Index (GPI) includes:
education, economic activity, and parliamentary repre-
sentation [33]. The UN GII includes: reproductive health
(i.e., maternal mortality and adolescent fertility), em-
powerment (i.e., parliamentary representation and sec-
ondary education attainment) and labor force
participation [37, 38]. The Labour Force Gender Index
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(LFGI) includes: child-care responsibility, occupation
segregation, labor force participation, and level of educa-
tion [34].
The factors included in these gender equity indices
contributed to our second literature review examining
linkages between gender equity and health. Our litera-
ture search resulted in 205 articles on PubMed and 179
articles on Web of Science, of which 12 met inclusion
criteria [27, 38, 40–49]. These articles provided us with
a list of relevant indicators that are linked to gender
equity and health (Appendix C in Additional file 1). In
order to link health gains from vaccination to improve-
ments in gender equity, we examined this list for indica-
tors that could be quantitatively linked to improvements
in health from the literature. Bloom, et al. [27], provided
this quantitative linkage with an estimated relationship
between percentage improvement in health and percent-
age improvements in both labor force participation and
fertility rate. Relying on this study in combination with
the relationship between vaccination and health [50] as
well as the UN GII [35], we developed a flow diagram
for the conceptual framework linking vaccination to gen-
der equity, shown in Fig. 1.
Calculating healthy life expectancy
The results of our healthy life expectancy calculations
are shown in Fig. 2. The solid lines show the WHO life
expectancy curves and the points show WHO estimates
of healthy life expectancy at birth and at age 60 for
Tanzania, India, and the United Kingdom. The dotted
lines show our calculations of healthy life expectancy by
each year of age, anchoring on the previous curves and
healthy life expectancy estimates.
Impact of HPV vaccination
Overall, HPV vaccination is expected to decrease cer-
vical cancer cases and deaths by approximately 80% in
Tanzania, India, and the United Kingdom based on
PRIME projections. For women of reproductive age (15
to 49 years), the median percentage improvement in
healthy life expectancy due to reductions in cervical can-
cer cases and deaths is 51% in Tanzania, 52% in India,
and 49% in the United Kingdom. The impact that HPV
vaccination is projected to have in Tanzania, India, and
the United Kingdom is shown in Fig. 3.
Impact of HPV vaccination on gender equity dimensions
Assuming a 5% improvement in health from HPV vac-
cination translates to a 5.9% increase in female labor
force participation [27], years of employment gained
among women who averted cervical cancer by five-year
age of onset ranged from 165 to 920 years in Tanzania,
1404–9600 years in India, and 38–78 years in the United
Kingdom for women aged 15 to 49 years (Table 1). The
same 5% improvement in health and resulting fertility
reduction of 2.4% was estimated to lead to a correspond-
ing decrease in the maternal mortality ratio (per 100,000
live births) of 4.5%. This decline in maternal mortality
was associated with 1.4 fewer maternal deaths in
Tanzania, 2.3 fewer maternal deaths in India, and ap-
proximately no change in maternal deaths in the United
Kingdom.
The years of employment gained from improvements
in health due to reduced cervical cancer incidence also
contributes to increased economic output. The improve-
ments in economic productivity from years of employ-
ment gained by female workers could be approximately
$4.7 million in Tanzania, $24 million in India, and $18
million in the United Kingdom (in US$2015).
In our sensitivity analysis examining the lower range
with half the magnitude of this association, which as-
sumes that a 5% improvement in health from HPV vac-
cination translate to a 2.95% increase in female labor
force participation, years of employment gained among
women who averted cervical cancer ranged from 82 to
460 years in Tanzania, 702–4800 years in India, and 19–
39 years in the United Kingdom for women aged 15 to
49 years. In terms of economic productivity, this trans-
lated to approximately $2.4 million in Tanzania, $12 mil-
lion in India, and $8.9 million in the United Kingdom.
Assuming a 5% improvement in health from HPV vac-
cination translated to a 1.2% decrease in fertility rate, the
associated impact on maternal mortality was 0.72 mater-
nal deaths averted in Tanzania, 2.15 maternal deaths
averted in India, and approximately no change in mater-
nal deaths in the United Kingdom.
In our sensitivity analysis examining the upper range
with double the magnitude of association, which as-
sumed that a 5% improvement in health from HPV vac-
cination translate to a 11.8% increase in female labor
force participation, years of employment gained among
Fig. 1 Conceptual flow diagram. Note: [1] Feikin et al., 2016 [50]. [2] Bloom et al., 2016 [27]. [3] United Nations Development Programme,
2018 [35]
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Fig. 2 Estimated years of life expectancy and healthy life expectancy (HLE) for Tanzania, India, and the United Kingdom. *Note: The top curve for
each country represents World Health Organization (WHO) life expectancy estimates, which are adjusted down to our estimated healthy life
expectancy estimates in the bottom curve, anchoring on the HLE at birth and HLE at age 60 estimates from WHO [36]
Fig. 3 Impact of HPV vaccination on cervical cancer cases by age in a cohort of women vaccinated at 9 years old in Tanzania, India, and the
United Kingdom
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women who averted cervical cancer ranged from 330 to
1840 years in Tanzania, 2808–19,200 years in India, and
76–156 years in the United Kingdom for women aged 15
to 49 years. In terms of economic productivity, this
translated to approximately $9.4 million in Tanzania,
$48 million in India, and $36 million in the United King-
dom. Assuming a 5% improvement in health from HPV
vaccination translated to a 4.8% decrease in fertility rate,
the associated impact on maternal mortality was 2.9 ma-
ternal deaths averted in Tanzania, 8.6 maternal deaths
averted in India, and approximately no change in mater-
nal deaths in the United Kingdom.
Comparing GII scores calculated based on current
HPV vaccination levels and under the counterfactual
scenario of 0% HPV vaccination, improvements in labor
force participation and maternal survival were both asso-
ciated with a decrease in the level of gender inequality
(i.e., increase in the level of gender equity) in the three
countries of interest. Compared to the status quo GII
scores in Tanzania, India, and the United Kingdom
(0.537, 0.524, and 0.116, respectively), the absolute
changes in GII scores were small (0.0000021
(0.0000019–0.000013), 0.0000017 (0.0000017–
0.0000032), and 0.0000002 (0.0000002–0.0000004), re-
spectively) because cervical cancer is a rare outcome and
GII index scores are estimated on a 0–1 scale. While the
index comprises multiple dimensions, labor force par-
ticipation and maternal mortality ratio account for ap-
proximately 50% of the index score.
Discussion
We developed a conceptual framework that links vaccin-
ation and gender equity utilizing existing literature. In
our case study, we found that HPV vaccination could
help narrow socioeconomic gender disparities by quanti-
fying the main pathways by which HPV vaccination im-
proves health, which enables improvement in gender
equity indicators such as labor force participation and
maternal mortality ratios. Specifically, we found that the
years of employment gained among women with averted
cervical cancer ranged from 165 to 920 years in
Tanzania, 1404–9600 years in India, and 38–78 years in
the United Kingdom for women aged 15 to 49 years.
The averted maternal deaths among women with averted
cervical cancer was 1.4 in Tanzania and 2.3 in India.
These improvements likewise translate to improvements
in gender equity. While these improvements are small
when averaged over the entire population, the compo-
nents measured – labor force participation and maternal
mortality ratio – account for 50% of the index score.
While the magnitude of improvement we found is
small due to the rarity of cervical cancer, we have likely
underestimated the benefits. This is because our model
did not include many other benefits of HPV vaccination
such as indirect (herd) effects, social stigma associated
with cervical and other HPV-related cancers, reductions
in time-consuming and anxiety-inducing cervical screen-
ing and treatment rounds, as well as effects on non-
cervical HPV-related disease such as vulvar, vaginal, anal
and oropharyngeal cancers [21, 51]. We also only as-
sumed vaccination coverage of girls, per the WHO rec-
ommendations for routine immunization [52], whereas
many countries also vaccinate boys. However, even if
countries were to vaccinate both girls and boys, we
would still likely see a gender equity benefit due to the
health benefits of HPV vaccination primarily accruing
among girls [53]. Furthermore, we have only explored
two of the many pathways between improved health and
gender equity (via female labor participation and mater-
nal mortality) because of the availability of existing
models of these pathways and their inclusion in the GII.
In particular, the pathway between improved health and
gender equity via improvements in female educational
attainment is relevant [5, 8, 9, 38, 44, 46, 54], but ex-
cluded in this analysis due to limited data and the late
age of onset of cervical cancer. Additionally, given the
Table 1 Years of life saved and years of employment gained and maternal deaths averted among women with averted cervical
cancer in Tanzania, India, and the United Kingdom
Age
Group
Tanzania India United Kingdom
Years of
life saved
Years of
employment
gained
Maternal
deaths
averted
Years of
life saved
Years of
employment
gained
Maternal
deaths
averted
Years of
life saved
Years of
employment
gained
Maternal
deaths
averted
15–19 2672 313 0.03 45,643 2492 0.07 725 65 < 0.01
20–24 2386 278 0.03 41,474 2216 0.07 668 58 < 0.01
25–29 2107 242 0.04 37,345 1941 0.07 612 51 < 0.01
30–34 1836 203 0.05 33,259 1672 0.08 556 45 < 0.01
35–39 1578 165 0.05 29,218 1404 0.09 500 38 < 0.01
40–44 8510 819 0.43 176,959 7987 0.69 1121 78 < 0.01
45–49 10,652 920 0.80 234,004 9600 1.22 1076 66 < 0.01
Total 29,742 2939 1.43 597,902 27,312 2.29 5258 401 < 0.01
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late age of onset of HPV compared to other vaccine-
preventable diseases, it may be possible that the impact
of vaccination against childhood diseases could have a
larger impact on gender equity. Despite these limita-
tions, our work provides for the first time, to our know-
ledge, both a proof of concept and quantitative links
between vaccination and gender equity.
In this analysis, we selected HPV vaccination as a case
study for gender equity given that its health benefits are
predominantly in women [53]. If we examined a vaccine
that was more gender-neutral in the acquisition of
health benefits such as measles or rotavirus, health im-
provements among both men and women would impact
both labor force participation and fertility rates. Accord-
ing to Bloom, et al., male health improvements increase
the fertility rate, which would likewise decrease the fe-
male labor force participation rate [27]. Therefore, if a
health intervention such as vaccination improved the
health of both sexes equally, the macroeconomic effects
may be counteracting. However, given that an economy
has transitioned to a regime of “declining fertility and in-
creasing educational investments,” the dynamic equilib-
rium model developed by Bloom, et al., found that
gender-neutral health improvements still improved over-
all economic growth via female labor force participation
and declining fertility [27]. The paper further states that
health improvements among both sexes also supports
the transition from a high fertility regime to a low fertil-
ity regime. In the case of vaccination in LMICs, the net
improvement of a gender-neutral vaccination might
therefore lead to improvements in gender equity, al-
though likely to a lesser extent than an HPV vaccination
program. Hence, we can conclude that most
immunization programs are likely to contribute to gen-
der equity as long as they achieve equal uptake among
males and females.
Equity is a key criterion for health technology assess-
ments in many countries [55, 56] and by organizations
such as the Bill & Melinda Gates Foundation [57]. Up to
now, most of the literature around vaccines and equity
has focused on socioeconomic [58–60] and geographical
[61–63] dimensions of equity. Additionally, suggestions to
address gender equity and female empowerment as part of
the Sustainable Development Goals have focused on pol-
icies around dimensions of gender equity, rather than
health [17]. Our work shows that vaccines may also help
to narrow gender disparities by a conceptual framework
that links improvements in health to dimensions of gender
equity, and that the magnitude of such effects can be
quantified. Furthermore, we have shown that those effects
improve the same dimensions that have been identified as
essential to gender equity, where gaps still remain [17, 64].
Given the importance of gender equity to develop-
ment, this suggests that decision-making bodies such as
national immunization technical advisory groups
(NITAGs) and donors may wish to consider vaccine im-
pact on gender equity as one of the decision-making cri-
teria around new vaccine introductions. Future research
should be conducted to examine these gender equity
benefits beyond this case study of three countries from
the lens of HPV vaccination.
This analysis presents a number of limitations. First,
our conceptual framework and quantitative associations
rely on the available published literature, which remains
limited on this topic. Specifically, we rely heavily on
Bloom, et al. [27], which reports on a dynamic general
equilibrium model of economic development across
countries, and may not be generalizable to the settings
that we feature in this analysis. Additionally, as the per-
centages obtained from this model are applied across all
ages equally, the results of our analysis would be affected
if the age distribution of disease by country is heavily
skewed towards younger or older women. In order to
address this limitation, we conducted a sensitivity ana-
lysis on the impact of improvements in health on female
labor force participation and fertility with lower and
upper bounds of 0.5 and 2 times multipliers, which
would encompass environments where the age distribu-
tion of disease trends toward older women, i.e., lower re-
ductions in fertility and improvements in labor force
participation, or younger women, i.e., greater reductions
in fertility and improvements in labor force participa-
tion. Second, in order to preserve the decreased life ex-
pectancy at birth and the increased life expectancy for
individuals who survive infancy in our calculations of
healthy life expectancy, we applied a constant to life ex-
pectancy between birth and age 60, but did not apply
the constant beyond age 60. While this approximates the
trend of the life expectancy curve, this approach results
in a discontinuity at age 60 that should be smooth, but
is necessary to provide a reasonable estimate of healthy
life expectancy between age 60 and 100. Third, we as-
sumed that the relationship between health and equity is
the same across countries, but it may vary, as it contains
inherent cultural and infrastructural assumptions that
are not country-invariant. Fully addressing the relation-
ship between health and equity in each country would
require econometric analysis at the country level. We
were also unable to control for changes in female labor
force participation due to events unrelated to vaccin-
ation. Fourth, the individual-level impact of reduced cer-
vical cancer on female labor force participation and
fertility are less certain compared to vaccines which
cause sequelae from early childhood. We might still ex-
pect to see individual-level fertility effects with HPV vac-
cine due to health expectations, e.g., if women are less
likely to expect to be ill and have fertility affected in later
life due to cervical cancer, then they may be more
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inclined to invest in education, delay childbirth, or even
reduce fertility. Additionally, a woman who has cervical
cancer and recovers may well have her fertility negatively
affected since many of the treatments for cervical cancer
affect fertility [65]. In order to address this uncertainty,
we have conducted a sensitivity analysis on the fertility
effect. Finally, the model presented here does not repre-
sent a causal relationship between HPV vaccination and
gender equity.
While our analysis focused on reductions in gender in-
equity from overall improvements to healthy life expect-
ancy, Finlay and Lee (2018) have examined the causal
linkages between improvements in reproductive health,
specifically, and the economic empowerment dimensions
of gender equity [66]. This analysis relied on empirical
evidence to draw similar conclusions that reproductive
health improvements can and do empower women
through effects on education, labor force participation,
and childbearing. However, our analysis takes these re-
sults a step further by providing a proof of concept
model for how a public health intervention such as vac-
cination could have a quantifiable impact on gender
equity. Finally, there remains uncertainty in improve-
ments in health, labor force participation, and fertility rate,
particularly as applied to these specific country contexts.
However, we hope to have addressed part of this uncer-
tainty by including ranges from sensitivity analyses.
Conclusions
Gender equity is one of the United Nations’ Sustainable
Development Goals and a key dimension of inclusive
economic growth. It has been associated with improve-
ments in health outcomes for women and children, in
addition to economic growth. This proof of concept
model is a starting point to inform future health and
economic analyses that might incorporate the impact of
gender equity as an additional impact of vaccination in
improving the health and well-being of the population.
Reduced HPV incidence may lead to improved gender
equity through improvements in female contributions to
the labor market and economic productivity, improve-
ments in female education, lower fertility, and reduced
youth dependency.
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